Brief: Brickell Biotech Acquires Exclusive Rights To Phase 1-Ready Dyrk1a Inhibitor Program And Novel Platform Targeting Autoimmune And Inflammatory Diseases

Fresh Tracks Therapeutics

01/09/2021 12:29

Sept 1 (Reuters) - Brickell Biotech Inc  BBI.O :
    * BRICKELL BIOTECH ACQUIRES EXCLUSIVE RIGHTS TO PHASE
1-READY
DYRK1A INHIBITOR PROGRAM AND NOVEL PLATFORM TARGETING AUTOIMMUNE
AND INFLAMMATORY DISEASES
    * BRICKELL BIOTECH INC - ACQUISITION INCLUDES RIGHTS TO
PLATFORM
OF DYRK1A INHIBITORS
    * BRICKELL BIOTECH INC - BRICKELL WILL MAKE A ONE-TIME
PAYMENT TO
VORONOI OF $2.5 MILLION IN CASH AND $2.5 MILLION IN SHARES OF
BRICKELL COMMON STOCK
    * BRICKELL BIOTECH INC - NUMBER OF SHARES TO BE ISSUED TO
VORONOI
IS BASED ON A PRICE OF $0.89 PER SHARE

Source text for Eikon:  ID:nGNXcgT0Sf 
Further company coverage:  BBI.O 

 ((Reuters.Briefs@thomsonreuters.com;))